List of nationally authorised medicinal products

Size: px
Start display at page:

Download "List of nationally authorised medicinal products"

Transcription

1 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.

2 BROMAZEPAM ARROW 1,5 mg, comprimé National Number not available ARROW GENERIQUES FR Lexatin 1,5 mg cápsulas duras not available ROCHE FARMA, S.A. ES Lexatin 3 mg cápsulas duras not available ROCHE FARMA, S.A. ES Lexatin 6 mg capsulas duras not available ROCHE FARMA, S.A. ES LEXOMIL ROCHE not available ROCHE FR COMPRIME-BAGUETTE, comprimé quadrisécable LEXOMIL ROCHE not available ROCHE FR COMPRIME-BAGUETTE, comprimé quadrisécable LEXOMIL ROCHE not available ROCHE FR COMPRIME-BAGUETTE, comprimé quadrisécable Lexotan not available 6517 ROCHE A/S DK Lexotan not available 6518 ROCHE A/S DK Lexotan 1,5 mg capsule rigide not available ROCHE S.P.A. IT EMA/303456/2018 Page 2/7

3 Lexotan 1,5 mg compresse National Number not available ROCHE S.P.A. IT Lexotan 1,5 mg not available ROCHE FARMACÊUTICA Lexotan 1,5 mg not available ROCHE FARMACÊUTICA Lexotan 1.5 mg tablets not available PA 50/49/1 ROCHE PRODUCTS LTD IE Lexotan 2,5 mg/ml gocce orali soluzione not available ROCHE S.P.A. IT Lexotan 3 mg capsule rigide not available ROCHE S.P.A. IT Lexotan 3 mg compresse not available ROCHE S.P.A. IT Lexotan 3 mg comprimés not available BE N.V. ROCHE S.A. BE Lexotan 3 mg comprimés not available 0178/ N.V. ROCHE S.A. LU EMA/303456/2018 Page 3/7

4 Lexotan 3 mg National Number not available ROCHE FARMACÊUTICA Lexotan 3 mg not available ROCHE FARMACÊUTICA Lexotan 3 mg tablets not available PA 50/49/2 ROCHE PRODUCTS LTD IE Lexotan 3 mg Tablets not available MA060/00501 ROCHE PRODUCTS LTD MT Lexotan 3 mg tabletten not available BE N.V. ROCHE S.A. BE Lexotan 3 mg Tabletten not available BE N.V. ROCHE S.A. BE Lexotan 3 mg Tabletten not available 0178/ N.V. ROCHE S.A. LU Lexotan 3 mg töflur not available (IS) ROCHE A/S IS Lexotan 6 mg capsule rigide not available ROCHE S.P.A. IT EMA/303456/2018 Page 4/7

5 National Number Lexotan 6 mg comprimés not available BE N.V. ROCHE S.A. BE Lexotan 6 mg comprimés not available 0178/ N.V. ROCHE S.A. LU Lexotan 6 mg not available ROCHE FARMACÊUTICA Lexotan 6 mg not available ROCHE FARMACÊUTICA Lexotan 6 mg tabletten not available BE N.V. ROCHE S.A. BE Lexotan 6 mg Tabletten not available BE N.V. ROCHE S.A. BE Lexotan 6 mg Tabletten not available 0178/ N.V. ROCHE S.A. LU Lexotan 6 mg töflur not available (IS) ROCHE A/S IS Lexotan, 3 mg, tabletki not available R/1836 ROCHE POLSKA SP.O.O. PL EMA/303456/2018 Page 5/7

6 National Number Lexotan, 6 mg, tabletki not available R/0946 ROCHE POLSKA SP.O.O. PL Lexotanil not available ROCHE AUSTRIA GMBH AT Lexotanil not available 24191/ ROCHE (HELLAS) SA GR Lexotanil not available 49715/16/ ROCHE (HELLAS) SA GR Lexotanil not available 24192/ ROCHE (HELLAS) SA GR Lexotanil "Roche" 3 mg - Tabletten not available ROCHE AUSTRIA GMBH AT Lexotanil 1,5 mg tabletes not available ROCHE LATVIJA SIA LV Lexotanil 1,5 mg tabletės not available LT/1/94/0551/001 UAB "ROCHE LIETUVA" LT Lexotanil 3 mg tabletes not available ROCHE LATVIJA SIA LV EMA/303456/2018 Page 6/7

7 National Number Lexotanil 3 mg tabletės not available LT/1/94/0551/002 UAB "ROCHE LIETUVA" LT Lexotanil, 1,5 mg tabletid not available ROCHE EESTI OÜ EE Lexotanil, 3 mg tabletid not available ROCHE EESTI OÜ EE Lexotanil not available S00089 G.A. STAMATIS & CO LTD CY Лексотан 3 mg таблетки not available ІІ ROCHE BULGARIA EOOD BG EMA/303456/2018 Page 7/7

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30

More information

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Initial (Full) Marketing Authorisation application accelerated assessment timetables

Initial (Full) Marketing Authorisation application accelerated assessment timetables 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/00000227/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

European Medicines Agency decision

European Medicines Agency decision EMA/574564/2017 European Medicines Agency decision P/0278/2017 of 4 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for Japanese encephalitis vaccine (inactivated,

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 31 May 2018 EMA/CHMP/258276/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Dabigatran etexilate, hard capsules, 75 mg, 110 mg and 150 mg productspecific bioequivalence

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 February 2018 EMA/208334/2018 Human Medicines Evaluation Division Active substance: ibuprofen / pseudoephedrine Procedure no.: PSUSA/00001711/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

European Medicines Agency decision

European Medicines Agency decision EMA/497687/2017 European Medicines Agency decision P/0245/2017 of 4 September 2017 on the refusal of a paediatric investigation plan and on the refusal of a deferral and on the granting of a waiver for

More information

European Medicines Agency decision

European Medicines Agency decision EMA/741983/2016 European Medicines Agency decision P/0324/2016 of 2 December 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta), (EMEA-000498-PIP01-08-M06)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/208387/2017 European Medicines Agency decision P/0089/2017 of 6 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for melatonin (Circadin), (EMEA-000440-PIP02-11-M05)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/761887/2015 European Medicines Agency decision P/0307/2015 of 21 December 2015 on the acceptance of a modification of an agreed paediatric investigation plan for odanacatib (EMEA- 001123-PIP01-11-M03)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/348027/2017 European Medicines Agency decision P/0166/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for aciclovir (Sitavig and associated names),

More information

European Medicines Agency decision

European Medicines Agency decision EMA/776083/2014 European Medicines Agency decision P/0001/2015 of 7 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for linagliptin (Trajenta) (EMEA-000498-PIP01-08-M04)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/654883/2017 European Medicines Agency decision P/0312/2017 of 30 October 2017 on the acceptance of a modification of an agreed paediatric investigation plan for cabotegravir (EMEA- 001418-PIP01-13-M01)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/757980/2016 European Medicines Agency decision P/0313/2016 of 21 December 2016 on the agreement of a paediatric investigation plan for complex of povidone and iodine / dexamethasone (SHP640) (EMEA-001936-PIP01-16)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/120432/2017 European Medicines Agency decision P/0069/2017 of 3 April 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA-001501-PIP01-13-M04) in

More information

European Medicines Agency decision

European Medicines Agency decision EMA/137097/2017 European Medicines Agency decision P/0073/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for

More information

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016

Draft Agreed by Pharmacokinetics Working Party February Adoption by CHMP for release for consultation 1 April 2016 15 December 2016 Committee for Medicinal Products for Human Use (CHMP) Everolimus tablets 0.25 mg, 0.5 mg, 0.75 mg and 1 mg; 2.5 mg, 5 mg and 10 mg, dispersible tablets 0.1 mg and 0.25 mg; 2 mg, 3 mg and

More information

European Medicines Agency decision

European Medicines Agency decision EMA/398442/2016 European Medicines Agency decision P/0191/2016 of 15 July 2016 on the acceptance of a modification of an agreed paediatric investigation plan for agomelatine (Valdoxan, Thymanax), (EMEA-001181-PIP01-11-M03)

More information

Interested parties (organisations or individuals) that commented on the draft document as released for consultation.

Interested parties (organisations or individuals) that commented on the draft document as released for consultation. 25 January 2018 EMA/CHMP/729976/2017 Committee for Medicinal Products for Human Use (CHMP) Overview of comments received on 'Paracetamol oral use, immediate release formulations product-specific bioequivalence

More information

European Union herbal monograph on Pistacia lentiscus L., resin (mastix)

European Union herbal monograph on Pistacia lentiscus L., resin (mastix) 7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union

More information

European Medicines Agency decision

European Medicines Agency decision EMA/434825/2017 European Medicines Agency decision P/0235/2017 of 9 August 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral for venetoclax (Venclyxto), (EMEA-002018-PIP02-16)

More information

European Union herbal monograph on Eschscholzia californica Cham., herba

European Union herbal monograph on Eschscholzia californica Cham., herba 28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European

More information

European Medicines Agency decision

European Medicines Agency decision EMA/357972/2017 European Medicines Agency decision P/0173/2017 of 3 July 2017 on the acceptance of a modification of an agreed paediatric investigation plan for colistimethate sodium (Colobreathe), (EMEA-000176-PIP01-07-M05)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/848760/2017 European Medicines Agency decision P/0033/2018 of 30 January 2018 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M10)

More information

Q&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015

Q&A on Off-Label Use. EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Proposal in response to EFPIA paper of 3 rd October 2014 EMA Industry Stakeholder Platform - Operation of EU Pharmacovigilance Legislation 12 January 2015 Presented by Sabine Brosch (EMA) and Anja van

More information

Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance

Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg product-specific bioequivalence guidance 31 May 2018 EMA/CHMP/158772/2016/Rev.1 Committee for Medicinal Products for Human Use (CHMP) Prasugrel hydrochloride film-coated tablets 5 mg and 10 mg Draft Agreed by Pharmacokinetics Working Party April

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

European Medicines Agency decision

European Medicines Agency decision EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)

More information

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on 11/01/2019 PL Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

European Medicines Agency decision

European Medicines Agency decision EMA/501874/2008 European Medicines Agency decision P/0303/2016 of 4 November 2016 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for

More information

European Medicines Agency decision

European Medicines Agency decision EMA/106209/2017 European Medicines Agency decision P/0074/2017 of 17 March 2017 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for

More information

European Medicines Agency decision

European Medicines Agency decision EMA/156109/2018 European Medicines Agency decision P/0103/2018 of 19 March 2018 on the agreement of a paediatric investigation plan and on the granting of a deferral for plazomicin (sulfate) (EMEA-001639-PIP02-17)

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary

More information

European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos

European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos 29 September 2015 EMA/HMPC/41108/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Helichrysum arenarium (L.) Moench, flos Draft Discussion in Working Party on European

More information

European Union herbal monograph on Peumus boldus Molina, folium

European Union herbal monograph on Peumus boldus Molina, folium 22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party

More information

European Union herbal monograph on Ruscus aculeatus L. rhizoma

European Union herbal monograph on Ruscus aculeatus L. rhizoma 30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European

More information

European Medicines Agency decision

European Medicines Agency decision EMA/281879/2015 European Medicines Agency decision P/0097/2015 of 8 May 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for human

More information

European Medicines Agency decision

European Medicines Agency decision EMA/38339/2017 European Medicines Agency decision P/0021/2017 of 3 February 2017 on the acceptance of a modification of an agreed paediatric investigation plan for dupilumab (EMEA- 001501-PIP02-13-M02)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/75416/2018 European Medicines Agency decision P/0042/2018 of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel), (EMEA-000567-PIP01-09-M05)

More information

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

European Union herbal monograph on Glycine max (L.) Merr., lecithinum

European Union herbal monograph on Glycine max (L.) Merr., lecithinum 31 January 2017 EMA/HMPC/220599/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Glycine max (L.) Merr., lecithinum Final Discussion in Working Party on European Union

More information

European Medicines Agency decision

European Medicines Agency decision EMA/155875/2015 European Medicines Agency decision P/0062/2015 of 1 April 2015 on the acceptance of a modification of an agreed paediatric investigation plan for sitagliptin (Januvia), (EMEA-000470-PIP01-08-M09)

More information

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 10/08/2018 n/a

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on. 10/08/2018 n/a Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

European Medicines Agency decision

European Medicines Agency decision EMA/151867/2018 European Medicines Agency decision P/0107/2018 of 11 April 2018 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (Fasenra), (EMEA-001214-PIP01-11-M07)

More information

European Medicines Agency decision

European Medicines Agency decision EMA/605276/2014 European Medicines Agency decision P/0282/2014 of 28 October 2014 on the acceptance of a modification of an agreed paediatric investigation plan for lenvatinib (EMEA- 001119-PIP02-12-M02)

More information

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

New product information wording Extracts from PRAC recommendations on signals

New product information wording Extracts from PRAC recommendations on signals 25 January 2018 EMA/PRAC/8436/2018 Pharmacovigilance Risk Assessment Committee (PRAC) New product information wording Extracts from PRAC recommendations on signals Adopted at the 8-11 January 2018 PRAC

More information

European Medicines Agency decision

European Medicines Agency decision EMA/565636/2017 European Medicines Agency decision P/0282/2017 of 4 October 2017 on the granting of a product specific waiver for ramucirumab (Cyramza), (EMEA-002074-PIP01-16) in accordance with Regulation

More information

Supporting regulatory science outside the EU. The Article 58 procedure. An agency of the European Union

Supporting regulatory science outside the EU. The Article 58 procedure. An agency of the European Union Supporting regulatory science outside the EU The Article 58 procedure An agency of the European Union What is the Article 58 procedure? EMA, through its scientific committees, can carry out scientific

More information

European Union herbal monograph on Melilotus officinalis (L.) Lam., herba

European Union herbal monograph on Melilotus officinalis (L.) Lam., herba 28 March 2017 EMA/HMPC/44166/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Melilotus officinalis (L.) Lam., herba Draft Initial assessment Discussion in Working

More information

European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix

European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium reniforme Curt., radix 05 June 2018 EMA/HMPC/444244/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pelargonium sidoides DC and/or Pelargonium Final Initial assessment Discussion in Working

More information

European Medicines Agency decision

European Medicines Agency decision EMA/788583/2016 European Medicines Agency decision P/0363/2016 of 21 December 2016 on the agreement of a paediatric investigation plan and on the granting of a waiver for dipalmitoylphosphatidylcholine

More information

European Medicines Agency decision

European Medicines Agency decision EMA/43935/2015 European Medicines Agency decision P/0015/2015 of 30 January 2015 on the acceptance of a modification of an agreed paediatric investigation plan for eslicarbazepine (acetate) (Zebinix) (EMEA-000696-PIP02-10-M05

More information

CHMP List of questions

CHMP List of questions 28 June 2018 EMA/CHMP/346196/2018 To be addressed by the marketing authorisation holders for bacterial lysatescontaining medicinal products for respiratory conditions Referral under Article 31 of Directive

More information

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government

More information

European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba

European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba 24 November 2015 EMA/HMPC/712511/2014 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba Final Discussion

More information

Update on public hearing

Update on public hearing Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity

More information

European Medicines Agency decision

European Medicines Agency decision EMA/785816/2015 European Medicines Agency decision P/0294/2015 of 3 December 2015 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for

More information

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on 05/03/2018 PL

Commission. Product. Notification. Decision. Issued 2 / affected 3 amended on 05/03/2018 PL Procedural steps taken and scientific information after the authorisation Application Scope Opinion/ Commission Product Summary number Notification Decision Information 1 issued on Issued 2 / affected

More information

European Union herbal monograph on Symphytum officinale L., radix

European Union herbal monograph on Symphytum officinale L., radix 5 May 2015 EMA/HMPC/572846/2009 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Symphytum officinale L., radix Final Discussion in Working Party on Community monographs

More information